PRIVATE medical insurance premiums could snowball when cancer drug Herceptin is licensed for use within the NHS, warns a leading consultant.
Most insurers are expected to extend their cover to include the drug treatment – unless specific exclusions are made – although PMI costs will increase by up to £25,000 for each employee treated. Mercer...
This week's edition of Professional Pensions is out now.
Industry Voice: Sponsored by Eaton Vance
BNY Mellon has launched a range of reporting tools to help institutional investor clients track and evaluate portfolio investments based on environmental, social and governance (ESG) issues.
PP speaks to BESTrustees director Heather McGuire about her views on the CMA's review into the investment consultant and fiduciary management markets.